logo
Plus   Neg
Share
Email

Merck To Acquire Peloton - Quick Facts

Merck (MRK) has reached an agreement with Peloton Therapeutics, Inc., under which a Merck unit will acquire Peloton for an upfront payment of $1.05 billion. Peloton shareholders will receive a further $1.15 billion on achievement of certain milestones.

Peloton Therapeutics is a clinical-stage biopharmaceutical company focused on the development of small molecule therapeutic candidates for the treatment of patients with cancer and other non-oncology diseases. Peloton's lead candidate PT2977, an oral HIF-2a inhibitor, is in late-stage development for renal cell carcinoma.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. is taking necessary precautions including Covid-19 testing for those employees returning to work at its headquarters in Silicon Valley, Bloomberg reported citing people familiar with the process. The company, which opened its main Apple Park office in May bringing back some hardware and software engineers, plans the gradual reopening of the building keeping the coronavirus safeguards. A U.S. appeals court has blocked the sales of Bayer AG's dicamba-based Xtendimax in the United States. The three-judge panel in the U.S. Court of Appeals for the Ninth Circuit ruled that the US Environmental Protection Agency (EPA) overstated the protections and substantially understated or ignored the risks related to the use of dicamba-based herbicides. Tesla Chief Executive Officer Elon Musk has called for a breakup of Amazon after the online retail giant refused to publish an upcoming book about COVID-19. Writer Alex Berenson said on Twitter that Amazon refused to publish his booklet about the coronavirus as it did not comply with the company's guidelines. Berenson is a former New York Times reporter.
Follow RTT